Casa
dale moreno baji

Pyrazole Urea-Based Inhibitors of p38 MAP Kinase: From Lead Compound to Clinical Candidate

Por um escritor misterioso

Descrição
Pyrazole Urea-Based Inhibitors of p38 MAP Kinase: From Lead Compound to Clinical Candidate
Figure 1 from 'Reverse' alpha-ketoamide-based p38 MAP kinase
Pyrazole Urea-Based Inhibitors of p38 MAP Kinase: From Lead Compound to Clinical Candidate
Pyrazole Urea-Based Inhibitors of p38 MAP Kinase: From Lead
Pyrazole Urea-Based Inhibitors of p38 MAP Kinase: From Lead Compound to Clinical Candidate
p38 mitogen‐activated protein kinase: Functions and targeted
Pyrazole Urea-Based Inhibitors of p38 MAP Kinase: From Lead Compound to Clinical Candidate
p38 MAPK inhibitor, BIRB 796, opnMe
Pyrazole Urea-Based Inhibitors of p38 MAP Kinase: From Lead Compound to Clinical Candidate
BIRB 796 (Doramapimod) P38 MAPK inhibitor,cell permeable and
Pyrazole Urea-Based Inhibitors of p38 MAP Kinase: From Lead Compound to Clinical Candidate
Pyrazole Urea-Based Inhibitors of p38 MAP Kinase: From Lead
Pyrazole Urea-Based Inhibitors of p38 MAP Kinase: From Lead Compound to Clinical Candidate
p38 mitogen‐activated protein kinase: Functions and targeted
Pyrazole Urea-Based Inhibitors of p38 MAP Kinase: From Lead Compound to Clinical Candidate
Molecules, Free Full-Text
Pyrazole Urea-Based Inhibitors of p38 MAP Kinase: From Lead Compound to Clinical Candidate
Inflammatory but not mitogenic contexts prime synovial fibroblasts
de por adulto (o preço varia de acordo com o tamanho do grupo)